Inhaled corticosteroids (ICS) are the FDA-indicated treatment of choice in preventing asthma exacerbations in patients with persistent asthma. Persistent asthma is classified by symptoms more than two days a week, more than three nighttime awakenings per month, more than twice a week use of short-acting beta-2 agonists for symptom control, or any limitation of normal activity due to asthma. Regular use of these medications reduces the frequency of asthma symptoms, bronchial hyperresponsiveness, risk of serious exacerbations, and improves quality of life. These medications are initiated in a stepwise fashion based on the frequency and severity of the asthma symptoms. Low-, medium-, and high-dose inhaled corticosteroids are available to treat mild, moderate, and severe persistent asthma respectively. If inhaled corticosteroids alone are not adequate in controlling a patient's asthma symptoms, other controller medications such as long-acting beta agonists or leukotriene receptor antagonists also may be started. Asthma controller medications often are used in conjunction with short-acting beta agonists such as albuterol as part of an asthma action plan to address acute and chronic symptoms.
Inhaled corticosteroids also are prescribed off-label (non-FDA approved) for management of chronic obstructive pulmonary disease (COPD). Up to 40% to 50% of patients with COPD receive inhaled corticosteroid therapy. Data suggests that these medications decreased the number of exacerbations and may slow the progression of lung disease. There is, however, minimal impact of inhaled corticosteroids on lung function and mortality. Inhaled corticosteroids are most often used in COPD as an adjunct to long-acting inhaled bronchodilators but may be initiated earlier if there is an asthmatic component in a given patient’s lung disease.
Inhaled corticosteroids have potent glucocorticoid activity and work directly at the cellular level by reversing capillary permeability and lysosomal stabilization to reduce inflammation. The onset of action is gradual and may take anywhere from several days to several weeks for maximal benefit with consistent use. Metabolism is through the hepatic route, with a half-life elimination of up to 24 hours.
These drugs are administered through the inhalation route directly to their sites of action. This decreases the dose required for the desired effect as it bypasses the first-pass metabolism in drugs taken orally. The reduced systemic bioavailability also minimizes side effects. Inhaled corticosteroids come in liquid capsule formulations that are given through a nebulizer machine, metered dose inhalers (MDI) administered through spacers, and dry powder inhalers (DPI). Advantages and disadvantages of each are as follows:
Metered Dose Inhalers (MDI)
Dry Powder Inhaler (DPI)
Drug deposition of inhaled corticosteroids in children older than five are similar to that of adults, so the method of administration of ICS in these ages groups should be decided based on patient and family preference. However, toddlers and infants cannot reliably generate a sufficient inspiratory flow rate to use dry powder inhalers, so this method of delivery is not recommended for this age group. It is recommended that young children either use a nebulizer or MDI with mask and spacer to deliver inhaled corticosteroids.
Many different brands of inhaled corticosteroids are available on the market with similar efficacy between the formulations. Widely used inhaled corticosteroids include budesonide, fluticasone, beclomethasone, flunisolide, mometasone, and triamcinolone.
Local adverse effects of inhaled corticosteroids include dysphonia, oral candidiasis, reflex cough, and bronchospasm. These adverse effects are less common with low-dose inhaled corticosteroids than with high-dose inhaled corticosteroids. These adverse effects are also mitigated by spacer use when taking the medication via metered dose inhalers.
Up to 60% of patients report dysphonia while using inhaled corticosteroids. It is due to myopathy of the laryngeal muscles and mucosal irritation, and it is reversible when the treatment is withdrawn. Oral candidiasis (thrush) is another common complaint among users of inhaled corticosteroids. This risk is increased in elderly patients and patients who are also taking oral steroids, high dose ICS, or antibiotics. Laryngeal and esophageal candidiasis also has been described in the literature. It is advised to have the patient rinse their mouth out after ICS use to prevent oral candidiasis. Treatments for candidiasis include clotrimazole, miconazole, and nystatin.
Inhaled corticosteroid use has been associated with a reduction in growth velocity in children with asthma. However, these effects in low doses of inhaled corticosteroids are small, nonprogressive and potentially reversible. Inadequate control of asthma also is associated with reductions in growth velocity, and early intervention with inhaled corticosteroids significantly improves asthma control. Thus, the benefits of ICS use outweighs the risk. Other potential systemic adverse effects of inhaled corticosteroids are rare and/or clinically insignificant, including cataracts, glaucoma, hypothalamic-pituitary-adrenal axis dysfunction, and impaired glucose metabolism. Symptomatic patients who are on long-term, inhaled corticosteroids should be screened for these conditions, or asymptomatic patients on the long-term, high-dose ICS.
There is conflicting evidence on the effect of inhaled corticosteroids on bone metabolism and osteoporosis. High doses of ICS are associated with increased risk of fracture. Adult patients on chronic ICS therapy should undergo bone density measurement. Routine testing of bone density in children is not needed, but supplementation with adequate vitamin D and calcium is recommended.
There are few absolute contraindications to the various inhaled corticosteroids available in the United States. These include hypersensitivity to the medication and severe hypersensitivity to milk proteins/lactose. Dry powder inhalers often contain lactose as a stabilizing agent. Though not intentional, there have been reports of milk protein contamination within lactose-containing medications including dry powdered inhalers. Therefore, in patients with severe milk protein or lactose allergies, DPI asthma medications are contraindicated. Additional contraindications in Canadian labeling include untreated fungal, bacterial, and tubercular infections of the respiratory tract. Inhaled corticosteroids are recommended for treating asthma during pregnancy. Maternal ICS use during pregnancy has not been shown to increase the risk of congenital malformations or impaired fetal growth.